表紙
市場調査レポート

皮膚科処方薬の世界市場 第9版:抗ニキビ、アンチエイジング、皮膚炎、抜け毛、乾癬、皮膚癌、肝斑、および脂漏症の治療

World Market for Prescription Dermatological Drugs, 9th Edition (Anti-acne, Anti-aging, Dermatitis, Hair Loss, Psoriasis, Skin Cancer, Melasma and Seborrhea Treatments)

発行 Kalorama Information 商品コード 233324
出版日 ページ情報 英文 446 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.39円で換算しております。
Back to Top
皮膚科処方薬の世界市場 第9版:抗ニキビ、アンチエイジング、皮膚炎、抜け毛、乾癬、皮膚癌、肝斑、および脂漏症の治療 World Market for Prescription Dermatological Drugs, 9th Edition (Anti-acne, Anti-aging, Dermatitis, Hair Loss, Psoriasis, Skin Cancer, Melasma and Seborrhea Treatments)
出版日: 2015年08月19日 ページ情報: 英文 446 Pages
概要

世界の皮膚科処方薬市場における主な促進要因として、世界的な人口の高齢化、新製品と技術、および加齢・皮膚へのダメージの影響を改善するライフスタイル治療への注目が挙げられます。医薬品産業内では、全体として、金融不況、統合、および経済の低迷が市場へ影響を及ぼしています。

当レポートは、世界の皮膚科処方薬市場を取り上げ、抗ニキビ、アンチエイジング、皮膚炎、抜け毛、乾癬、皮膚癌、肝斑、および脂漏症など、様々な皮膚疾患を治療するための処方薬を詳細に分析し、それぞれの市場規模と研究開発動向、将来の予測をまとめるとともに、主要な市場参入企業のプロファイルも提供しています。

第1章 エグゼクティブサマリー

第2章 イントロダクション

  • 皮膚の構造と機能
    • 表皮
    • 真皮
    • 皮下組織
    • 表皮付属器
  • 皮膚の機能
  • 加齢が皮膚に及ぼす影響
  • 皮膚の症状と治療
  • ファーマコキネティクス (薬物動態学)
    • 薬物吸収
    • 分配
    • バイオアベイラビリティ (生体利用性)
  • ドラッグデリバリー手法
  • 皮膚疾患の人口統計データ、発生率、および罹患率

第3章 課題と動向

  • 患者の適合性
  • 美容皮膚科医
  • 日焼け止めの利用
  • 黒色腫 (メラノーマ) 生存率の低迷
  • 室内日焼けの問題
  • ホスファチジルグリセロールと乾癬
  • 新たな充填材オプション
  • 消費者の混乱
  • 乾癬の遺伝的連関
  • 生物学的皮膚科学
  • スイッチOTC (Rx-to-OTC Switch)
  • 薬用化粧品
    • 酸化防止剤
    • ポリペプチド
  • 遠隔皮膚科学
  • 補償問題
  • 市場は低侵襲処置へ向かう
  • メディスパ
    • 社会の外見に対するこだわり
  • 規制の影響:米国・世界
  • 健康保険プログラム・治療費の影響
  • 競合の影響因子:市場・治療モダリティへの影響
  • レーザー治療
  • ナローバンドUVB
  • 光線力学的療法
  • PYCR1 遺伝子
  • クレジットカード条件の変化
  • 患者保護並びに医療費負担適正化法 (PPACA)
  • Thermage
  • BRAF遺伝子
  • 新たな経口薬とニキビの研究
  • 皮膚治療用合成脂質
  • ドラッグデリバリーの重要性
  • 産業の投稿

第4章 坑ニキビおよび酒さ処方薬

  • 疾患の概要
  • 製品概要
    • 過酸化ベンゾイル
      • 製品の説明
      • 現在のサプライヤー
    • レチノイド
      • 局所処方薬
        • オールトランスレチノイン酸 (トレチノイン)
        • アダパレン
        • タザロテン
      • 全身処方薬
        • イソトレチノイン
      • 現在のサプライヤー
    • 抗生物質
      • 製品の説明
        • アゼライン酸
        • クリンダマイシン
        • エリスロマイシン
        • メトロニダゾール
        • その他
      • 現在のサプライヤー
    • 経口避妊薬
  • 研究開発
  • 市場規模と成長
    • 世界市場
    • 地域別市場
      • 米国
      • 欧州
      • 日本
      • その他
  • 市場の将来
  • 競合分析

第5章 アンチエイジングおよび光損傷処方薬

  • 概要
  • 製品概要
    • 角質溶解薬
    • 保湿薬
    • レチノイド
    • 日焼け止め
    • ボトックス・充填剤
  • 研究開発
  • 市場規模と成長
    • 世界市場
    • 地域別市場
      • 米国
      • 欧州
      • 日本
      • その他
  • 市場の将来
  • 競合分析

第6章 皮膚炎および脂漏症処方薬

  • 概要
  • 製品概要
    • 局所コルチコステロイド薬
    • 全身コルチコステロイド薬
    • その他の製品
  • 研究開発
  • 市場規模と成長
    • 世界市場
    • 地域別市場
      • 米国
      • 欧州
      • 日本
      • その他
  • 市場の将来
  • 競合分析

第7章 抗真菌処方薬

  • 概要
  • 製品概要
    • 全身処方薬
    • 局所処方薬
  • 研究開発
  • 市場規模と成長
    • 世界市場:タイプ別
    • 地域別市場
  • 市場の将来
  • 競合分析

第8章 抜け毛および脱毛処方薬

  • 概要
  • 製品概要
    • 抗アンドロゲン
    • アンドロゲン阻害薬
    • その他の治療薬
  • 研究開発
  • 市場規模と成長
  • 世界市場
  • 地域別市場
  • 市場の将来
  • 競合分析

第9章 高色素沈着および肝斑処方薬

  • 概要
  • 製品概要
  • 市場規模と成長
  • 研究開発
  • 世界市場
  • 地域別市場
  • 市場の将来
  • 競合分析

第10章 乾癬処方薬

  • 概要
  • 製品概要
    • 主な局所乾癬製品
    • 主な全身乾癬製剤
    • 光線療法
    • 生物製剤
  • 研究開発
  • 市場規模と成長
  • 世界市場
  • 地域別市場
  • 市場の将来
  • 競合分析

第11章 皮膚癌処方薬

  • 概要
    • 非黒色腫皮膚癌
      • 紫外線角化症
      • 基底細胞癌
      • 扁平上皮細胞癌
      • 皮膚T細胞性リンパ腫
      • ディスプラスチック・ニーバス症候群
    • 悪性黒色腫
  • 製品概要
  • 研究開発
  • 市場規模と成長
  • 世界市場
  • 地域別市場
  • 市場の将来
  • 競合分析

第12章 その他の皮膚疾患治療薬

  • 概要
    • 坑ウィルス剤
    • 坑寄生虫剤
  • 製品概要
    • 坑ウィルス剤
    • 坑寄生虫剤
  • その他の皮膚関連製品
  • 研究開発
  • 市場規模と成長
    • 世界市場
  • 地域別市場
  • 市場の将来
  • 競合分析

第13章 世界市場のサマリー

  • 概要
  • 市場規模および予測
  • 市場分析:国別
    • 米国
    • 欧州
    • 日本
    • その他
  • 市場と競合分析

第14章 企業プロファイル

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: KLI5670561

The worldwide market for prescription dermatological drugs encompasses a wide variety of products that treat disorders of the skin as well as the effects of aging. It's a very dynamic time for the prescription dermatological drug industry. Consolidation, economic times, new technologies and genetic discoveries are among the trends that the industry is seeing.

The field of dermatology is currently experiencing a busy and interesting period and, as a result, the range of therapeutic options available to physicians has expanded.This Kalorama Information report, The Worldwide Market for Prescription Dermatological Drugs represents the ninth time that Kalorama has detailed the various categories of prescription dermatological drugs, describing the global market and identifying major market factors that may help to shape the market for treatments in the future.

The driving forces for this market include growth and aging of the worldwide population, new products and technologies, and focus on lifestyle treatments that improve the effects of aging and damage to the skin. Within the pharmaceutical industry as a whole, financial depression, consolidation and economic downturns have influenced the market.

The worldwide market for prescription dermatology drugs includes products in the following categories:

  • Prescription Acne and Rosacea Drugs
  • Prescription Antiaging and Photodamage Drugs
  • Prescription Dermatitis and Seborrhea Drugs
  • Prescription Fungal Infection Drugs
  • Prescription Hair Loss and Hair Removal Drugs
  • Prescription Hyperpigmentation/Melasma Drugs
  • Prescription Psoriasis Drugs
  • Prescription Skin Cancer Drugs
  • Other Prescription Skin Disorder Drugs

This report details the various categories of prescription dermatological drugs, describes the worldwide market for prescription dermatological drugs, and identifies major market factors that may help to shape the worldwide market for prescription dermatological drugs in the future.

The pharmaceutical industry is facing a tougher environment in general, due to harder regulations for gaining approvals for mainstream products, economic issues, and a dwindling pipeline of new products. Reliance on blockbuster drugs is all but over, causing a shift of focus for many drug research and development entities. By focusing on cosmetic medications, many manufacturers are realizing less scrutiny from the FDA and a growing need in the niche markets such as dermatology. This transition will play a role in the future development of the dermatological industry over the forecast period. The worldwide pharmaceutical sector has little choice but to continue expanding through mergers and acquisitions for some time to come. The sector is ripe for the picking, too, with the financial crisis having created an impressive buyer's market for larger companies, as smaller firms struggle to extend financing. True globalization of pharmaceuticals has arrived. Most of the growth in the next few years will be outside the US, Europe and Japan. It's a very dynamic time for the industry focusing on a worldwide market.

The information and analysis presented in this report are based on extensive interviews with senior management of top companies in the dermatology market. Background information was obtained from a comprehensive search of published literature and reports obtained from various government, business, medical trade, and international journals. Key information from published literature was used to conduct interviews with over 30 industry executives and product managers to validate and obtain expert opinion on current and future trends in the dermatological market. Interviews were also used to confirm and/or adjust market size estimates, as well as in formulating market projections.

All market data pertains to the worldwide market at the manufacturers' level. Data are expressed in current U.S. dollars. The base year for data was 2015. Historical data are provided for each of the years 2013 to 2014, and forecast data are provided for each of the years 2015 through 2020. Historical, base year, and forecast data are provided for each market segment. Market shares are provided for each market segment for the 2015 base year.

The following companies are profiled in this report:

  • Allergan Inc.
  • Allergan Inamed Corporation
  • Barrier Therapeutics, Inc
  • Bayer AG
  • PharmaDerm Pharmaceuticals, Inc
  • Bristol-Myers Squibb
  • Collagenex (now Galderma) Pharmaceuticals
  • Galderma S.A.
  • Genentech, Inc.
  • GlaxoSmithKline Plc
  • Johnson & Johnson (Janssen Pharmaceutica, Ortho Dermatological, Ortho-McNeil)
  • Medicis Pharmaceutical Corporation
  • Merck & Company, Inc.
  • Mylan Pharmaceuticals, Inc,
  • Novartis Pharmaceuticals Corporation
  • Nycomed Inc.
  • Pfizer, Inc.
  • Q-Med AB
  • Roche Group (F. Hoffmann-La Roche Ltd.)
  • Schering (now Merck)-Plough Corporation
  • Sinclair Pharma Plc.
  • SkinMedica
  • Stiefel Laboratories, Inc.
  • Valeant Pharmaceuticals, Inc.

Table of Contents

CHAPTER ONE: EXECUTIVE SUMMARY

  • Introduction
  • Scope and Methodology
  • Size and Growth of the Market
  • Issues and Trends Affecting Market
  • Competitor Analysis

CHAPTER TWO: INTRODUCTION

  • Structure and Function of the Skin
  • Epidermis
  • Dermis
  • Subcutaneous Tissue
  • Epidermal Appendages
  • Functions of the Skin
  • Effects of Aging on the Skin
  • Dermatological Conditions and Treatment
  • Pharmacokinetics
  • Drug Absorption
  • Distribution
  • Bioavailability
  • Drug Delivery Methods
  • Demographics of Skin Disorders, Incidence, and Prevalence

CHAPTER THREE: ISSUES AND TRENDS

  • Patient Compliance
  • Cosmetic Dermatologists
  • Sunscreen Use
  • Melanoma Survival Rates Falter
  • Indoor Tanning Issue
  • Phosphatidylglycerol and Psoriasis
  • New Filler Options
  • Consumer Confusion
  • Genetic Link to Psoriasis
  • Biologic Dermatology
  • Rx-to-OTC Switches
  • Cosmeceuticals
  • Antioxidants
  • Polypeptides
  • Teledermatology
  • Reimbursement Issues
  • Market Shift Towards less invasive Procedures
  • Medi-Spas
  • Combination therapies Thrive
  • Competitive, Economic, Social Forces Driving Market Demand
  • Society's Obsession with Physical Appearance
  • Regulatory Influences: US & International
  • International Authorities
  • U.S. FDA & Other Regulatory Agencies
  • Effects of Health Insurance Programs & Treatment Costs
  • Competitive Influences-Impact on Market & Treatment Modalities
  • Facial Skin--Bio-Physiology
  • The “Gray Areas” of Medicine
  • Laser Therapy
  • Narrowband Ultraviolet B
  • Photodynamic Therapy
  • PYCR1 Gene
  • Changes in Credit Card Terms
  • Patient Protection and Affordable Care Act
  • Thermage
  • BRAF Gene
  • New Oral Medications and Research for Acne
  • Synthetic Lipids for Skin Healing
  • Importance of Drug Delivery
  • Industry Consolidation

CHAPTER FOUR: PRESCRIPTION ANTIACNE AND ROSACEA DRUGS .69

  • Description of Disorders
  • Description of Products
  • Benzoyl Peroxide
  • Description of Products
  • Current Suppliers
  • Retinoids
  • Topical Formulations
  • All-trans Retinoic Acid (Tretinoin)
  • Adapalene
  • Tazarotene
  • Systemic Formulations
  • Isotretinoin
  • Current Suppliers
  • Antibiotics
  • Description of Products
  • Azelaic Acid
  • Clindamycin
  • Erythromycin
  • Metronidazole
  • Sodium Sulfacetamide
  • Others
  • Current Suppliers
  • Oral Contraceptives
  • Research and Development
  • Market Size and Growth
  • Worldwide Market
  • Markets by Geographical Region
  • United States
  • Europe
  • Japan
  • Rest of World
  • The Future of the Market
  • Competitive Analysis

CHAPTER FIVE: PRESCRIPTION ANTIAGING AND PHOTODAMAGE DRUGS

  • Overview
  • Description of Products
  • Keratolytics
  • Moisturizers
  • Retinoids
  • Sunscreens
  • Botox and Fillers
  • Research and Development
  • Market Size and Growth
  • Worldwide Market
  • Markets by Geographical Region
  • United States
  • Europe
  • Japan
  • Rest of World
  • The Future of the Market
  • Competitive Analysis

CHAPTER SIX: PRESCRIPTION DERMATITIS AND SEBORRHEA DRUGS

  • Overview
  • Description of Products
  • Topical Corticosteroids
  • Systemic Corticosteroids
  • Other Products
  • Research and Development
  • Market Size and Growth
  • Worldwide Market by Type
  • Markets by Geographical Region
  • United States
  • Europe
  • Japan
  • Rest of World
  • Future of the Market
  • Competitive Analysis

CHAPTER SEVEN: PRESCRIPTION ANTIFUNGAL DRUGS

  • Overview
  • Description of Products
  • Systemic Formulations
  • Terbinafine
  • Itraconazole
  • Fluconazole
  • Griseofulvin
  • Ketoconazole
  • Echinocandin
  • Current Suppliers
  • Topical Formulations
  • Polyenes
  • Azoles
  • Miconazole
  • Clotrimazole
  • Ketoconazole
  • Oxiconazole
  • Econazole
  • Sulconazole
  • Allylamines and Benzylamines
  • Naftifine
  • Terbinafine
  • Butenafine
  • Other Topical Formulations
  • Novel Products
  • Current Suppliers
  • Research and Development
  • Market Size and Growth
  • Worldwide Market by Type
  • Markets by Geographical Region
  • United States
  • Europe
  • Japan
  • Rest of World
  • Future of the Market
  • Competitive Analysis

CHAPTER EIGHT: PRESCRIPTION HAIR LOSS AND HAIR REMOVAL DRUGS

  • Overview
  • Description of Products
  • Antiandrogens
  • Androgen Inhibitors
  • Other Treatments
  • Research and Development
  • Market Size and Growth
  • Worldwide Market by Type
  • Markets by Geographical Region
  • United States
  • Europe
  • Japan
  • Rest of World
  • Future of the Market
  • Competitive Analysis

CHAPTER NINE: PRESCRIPTION HYPERPIGMENTATION/MELASMA AND DEPIGMENTING DRUGS

  • Overview
  • Description of Products
  • Market Size and Growth
  • Worldwide Market
  • Markets by Geographical Region
  • United States
  • Europe
  • Japan
  • Rest of World
  • Research and Development
  • The Future of the Market
  • Competitive Analysis

CHAPTER TEN: PRESCRIPTION PSORIASIS DRUGS

  • Overview
  • Description of Products
  • Selected Topical Psoriasis Products
  • Anthralin
  • Coal Tar
  • Methoxsalen
  • Second-generation Retinoids
  • Tazarotene
  • Topical Vitamin D
  • Vitamin D Analogs
  • Vanos
  • Vectical Ointment
  • Selected Systemic Psoriasis Preparations
  • Betamethasone
  • Cortisone Acetate
  • Cyclosporine
  • Hydrocortisone
  • Methotrexate
  • Olopatadine Hydrochloride
  • Tacrolimus
  • Light Therapy
  • Biologics
  • Novel Products
  • Research and Development
  • Market Size and Growth
  • Worldwide Market by Type
  • Markets by Geographical Region
  • United States
  • Europe
  • Japan
  • Rest of World
  • Future of the Market
  • Competitive Analysis

CHAPTER ELEVEN: PRESCRIPTION SKIN CANCER DRUGS

  • Overview
  • Nonmelanoma Skin Cancers
  • Actinic Keratoses
  • Basal Cell Carcinoma
  • Squamous Cell Carcinoma
  • Cutaneous T-cell Lymphoma
  • Dysplastic Nevus Syndrome
  • Malignant Melanoma
  • Description of Products
  • 5-Fluorouracil
  • Mechlorethamine/Nitrogen Mustard
  • Carmustine/BCNU (Topical)
  • Vinblastine (Intralesional) and Others
  • Research and Development
  • Market Size and Growth
  • Worldwide Market
  • Markets by Geographical Region
  • United States
  • Europe
  • Japan
  • Rest of World
  • The Future of the Market
  • Competitive Analysis

CHAPTER TWELVE: MISCELLANEOUS SKIN DISORDER DRUGS

  • Overview
  • Antivirals
  • Antiparasitics
  • Description of Products
  • Antivirals
  • Antiviral Drugs
  • Immunoenhancing Drugs
  • Current Suppliers
  • Antiparasitic Agents
  • Current Suppliers
  • Other Skin Related Products
  • Research and Development
  • Market Size and Growth
  • Worldwide Market
  • Markets by Geographical Region
  • United States
  • Europe
  • Japan
  • Rest of World
  • The Future of the Market
  • Competitive Analysis

CHAPTER THIRTEEN: WORLD MARKET SUMMARY

  • Overview
  • Total Market Size and Forecast
  • Market Analysis by Country
  • United States
  • Europe
  • Japan
  • Rest of World
  • Market and Competitive Analysis

CHAPTER FOURTEEN: CORPORATE PROFILES

  • AbbVie, Inc.
  • Allergan
  • Amgen, Inc.
  • Anacor Pharmaceuticals, Inc.
  • Astellas Pharma, Inc.
  • Bayer AG
  • Bristol-Myers Squibb
  • Galderma S.A.
  • Genentech, Inc.
  • GlaxoSmithKline Plc
  • Johnson & Johnson
  • Merck & Company, Inc.
  • Mylan N.V
  • Novartis Pharmaceuticals Corporation
  • Pfizer, Inc.
  • PharmaDerm
  • Stiefel
  • Sinclair IS Pharma Plc.
  • Stratus Pharmaceuticals, Inc.
  • Valeant Pharmaceuticals International

APPENDIX

LIST OF COMPANIES

TABLE OF EXHIBITS

CHAPTER ONE: EXECUTIVE SUMMARY

  • Table 1-1: The Worldwide Market for Prescription Dermatological Drugs 2013, 2015, and 2020
  • Figure 1-1: The Worldwide Market for Prescription Dermatological Drugs 2013, 2015, and 2020

CHAPTER TWO: INTRODUCTION

  • Table 2-1: Common Bases for Topical Dermatological Medications
  • Table 2-2: Worldwide Incidence and Prevalence of Selected Dermatologic Conditions

CHAPTER THREE: ISSUES AND TRENDS

  • Table 3-1: Selected Dermatological Rx-to-OTC Switches
  • Table 3-2: Cy 2015 Relative Value Units (Rvus) and Related Information Used In Determining Final Medicare Payments

CHAPTER FOUR: PRESCRIPTION ANTIACNE AND ROSACEA DRUGS

  • Table 4-1: Common Benzoyl Peroxide Formulations
  • Table 4-2: Common Retinoid Formulations
  • Table 4-3: Common Topical Antibiotic Formulations
  • Table 4-3 (continued): Common Topical Antibiotic Formulations
  • Table 4-3 (continued): Common Topical Antibiotic Formulations
  • Table 4-4: Common Oral Contraceptive Formulations
  • Table 4-5: Prescription Acne, Actinic Keratosis and Rosacea Formulations in Development
  • Table 4-6: The Worldwide Market for Prescription Acne and Rosacea Drugs by Type 2013- 2020
  • Figure 4-1: The Worldwide Market for Prescription Acne and Rosacea Drugs Revenues by Type, 2013-2020
  • Figure 4-2: The Worldwide Market for Prescription Acne and Rosacea Drugs Share by Type 2015
  • Figure 4-3: The Worldwide Market for Prescription Acne and Rosacea Drugs Share by Type 2020
  • Table 4-7: Top Five EU Countries Prescription Psoriasis Markets by Revenues and Percent 2015 (in millions $)
  • Table 4-8: Top Four Rest of World Countries Prescription Psoriasis Markets by Revenues and Percent 2015 (in millions $)
  • Table 4-9: The Worldwide Market for Prescription Antiacne and Rosacea Drugs by Geographical Region 2013-2020
  • Figure 4-4: The Worldwide Market for Prescription Antiacne and Rosacea Drugs Revenues by Geographical Region 2013-2020
  • Figure 4-5: The Worldwide Market for Prescription Antiacne and Rosacea Drugs Share by Geographical Region 2015
  • Figure 4-6: The Worldwide Market for Prescription Antiacne and Rosacea Drugs Share by Geographical Region 2020
  • Table 4-10: Worldwide Market for Prescription Antiacne and Rosacea Drugs Revenues and Market Share by Supplier 2015
  • Figure 4-7: Worldwide Market for Acne and Rosacea Drugs Market Share by Leading Supplier 2015

CHAPTER FIVE: PRESCRIPTION ANTIAGING AND PHOTODAMAGE DRUGS

  • Table 5-1: Common Prescription Keratolytic Formulations
  • Table 5-2: Occlusive Moisturizers-Categories of Ingredients
  • Table 5-3: Common Prescription Moisturizers
  • Table 5-4: Common Prescription Retinoids for Antiaging and Photodamage
  • Table 5-5: Common Prescription Sunscreens
  • Table 5-6: Other Prescription Antiaging and Photodamage Products
  • Table 5-7: Prescription Antiaging and Photodamage Formulations in Development
  • Table 5-8: The Worldwide Market Antiaging and Photodamage Drugs by Type 2013-2020
  • Figure 5-1: The Worldwide Market for Antiaging and Photodamage Drugs Revenues by Type 2013-2020
  • Figure 5-2: The Worldwide Market for Antiaging and Photodamage Drugs Share by Type 2015
  • Figure 5-3: The Worldwide Market for Antiaging and Photodamage Drugs Share by Type 2020
  • Table 5-9: Top Five EU Countries Prescription Antiaging and Photodamage Drug Markets by Revenues and Percent 2015
  • Table 5-10: Top Four Rest of World Countries Prescription Antiaging and Photodamage Drug Markets by Revenues and Percent 2015
  • Table 5-11: The Worldwide Market for Prescription Antiaging and Photodamage Drugs by Geographical Region 2013-2020
  • Figure 5-4: The Worldwide Market for Prescription Antiaging and Photodamage Drugs, Revenues by Geographical Region 2013-2020
  • Figure 5-5: The Worldwide Market for Antiaging and Photodamage Drugs Share by Geographical Region 2015
  • Figure 5-6: The Worldwide Market for Antiaging and Photodamage Drugs Share by Geographical Region 2020
  • Table 5-12: Worldwide Market for Prescription Antiaging and Photodamage Drugs Revenues and Market Share by Supplier 2015
  • Figure 5-7: Worldwide Market for Prescription Antiaging and Photodamage Drugs, Market Share by Leading Supplier 2015

CHAPTER SIX: PRESCRIPTION DERMATITIS AND SEBORRHEA DRUGS

  • Table 6-1: Common Prescription Topical Corticosteroid Preparations
  • Table 6-1 (continued): Common Prescription Topical Corticosteroid Preparations
  • Table 6-2: Common Prescription Systemic Corticosteroids
  • Table 6-3: Prescription Other Dermatitis Formulations
  • Table 6-4: Prescription Dermatitis Formulations in Development
  • Table 6-5: The Worldwide Market for Prescription Dermatitis and Seborrhea Drugs by Type 2013-2020
  • Figure 6-1: The Worldwide Market for Prescription Dermatitis and Seborrhea Drugs Revenues by Type 2013-2020
  • Figure 6-2: The Worldwide Market for Prescription Dermatitis and Seborrhea Drugs Share by Type 2015
  • Figure 6-3: The Worldwide Market for Prescription Dermatitis and Seborrhea Drugs Share by Type 2020
  • Table 6-6: Top Five EU Countries Prescription Dermatitis and Seborrhea Drug Markets by Revenues and Percent 2015 (in millions $)
  • Table 6-7: Top Four Rest of World Countries Prescription Dermatitis and Seborrhea Drug Markets by Revenues and Percent 2015 (in millions $)
  • Table 6-8: The Worldwide Market for Prescription Dermatitis and Seborrhea Drugs by Geographical Region 2013-2020
  • Figure 6-4: The Worldwide Market for Prescription Dermatitis and Seborrhea Drugs Revenues by Geographical Region 2013-2020
  • Figure 6-5: The Worldwide Market for Prescription Dermatitis and Seborrhea Drugs Share by Geographical Region 2015
  • Figure 6-6: The Worldwide Market for Prescription Dermatitis and Seborrhea Drugs Share by Geographical Region 2020
  • Table 6-9: Worldwide Market for Prescription Dermatitis and Seborrhea Drugs, Revenues and Market Share by Supplier 2015
  • Figure 6-7: Worldwide Market for Prescription Dermatitis and Seborrhea Drugs Market Share by Leading Supplier 2015

CHAPTER SEVEN: PRESCRIPTION ANTIFUNGAL DRUGS

  • Table 7-1: Common Prescription Systemic Antifungal Dermatological Formulations
  • Table 7-2: Common Prescription Topical Antifungal Dermatological Drugs
  • Table 7-3: Prescription Antifungal Dermatological Drugs in Development
  • Table 7-4: The Worldwide Market for Prescription Antifungal Dermatological Drugs by Type 2013-2020
  • Figure 7-1: The Worldwide Market for Prescription Antifungal Dermatological Drugs Revenues by Type 2013-2020
  • Figure 7-2: The Worldwide Market for Prescription Antifungal Dermatological Drugs, Share by Type 2015
  • Figure 7-3: The Worldwide Market for Prescription Antifungal Dermatological Drugs, Share by Type 2020
  • Table 7-5: Top Five EU Countries Prescription Dermatological Antifungal Drug Markets by Revenues and Percent 2015
  • Table 7-6: Top Four Rest of World Countries Prescription Dermatological Antifungal Drug Markets by Revenues and Percent 2015
  • Table 7-7: The Worldwide Market for Prescription Antifungal Dermatological Drugs by Geographical Region 2013-2020
  • Figure 7-4: The Worldwide Market for Prescription Antifungal Dermatological Drugs Revenues by Geographical Region 2013-2020
  • Figure 7-5: The Worldwide Market for Prescription Antifungal Dermatological Drugs, Share by Geographical Region 2015
  • Figure 7-6: The Worldwide Market for Prescription Antifungal Dermatological Drugs, Share by Geographical Region 2020
  • Table 7-8: Worldwide Market for Prescription Antifungal Dermatological Drugs Revenues and Market Share by Supplier 2015
  • Figure 7-7: Worldwide Market for Prescription Antifungal Dermatological Drugs Market Share by Leading Supplier 2015

CHAPTER EIGHT: PRESCRIPTION HAIR LOSS AND HAIR REMOVAL DRUGS

  • Table 8-1: Common Prescription Hair Loss or Hair Removal Formulations
  • Table 8-2: Prescription Hair Loss or Hair Removal Formulations in Development
  • Table 8-3: The Worldwide Market for Prescription Hair Loss and Hair Removal Drugs by Type 2013-2020
  • Figure 8-1: The Worldwide Market for Prescription Hair Loss and Hair Removal Drugs Revenues by Type 2013-2020
  • Figure 8-2: The Worldwide Market for Prescription Hair Loss and Hair Removal Drugs, Share by Type 2015
  • Figure 8-3: The Worldwide Market for Prescription Hair Loss and Hair Removal Drugs, Share by Type 2020
  • Table 8-4: Top Five EU Countries Prescription Dermatological Hair Loss and Hair Removal Drug Markets by Revenues and Percent 2015
  • Table 8-5: Top Four Rest of World Countries Prescription Dermatological Hair Loss and Hair Removal Drug Markets by Revenues and Percent 2015
  • Table 8-6: The Worldwide Market for Prescription Hair Loss and Hair Removal Drugs, Revenues by Geographical Region 2013-2020
  • Figure 8-4: The Worldwide Market for Prescription Hair Loss and Hair Removal Drugs, Revenues by Geographical Region 2013-2020
  • Figure 8-5: The Worldwide Market for Prescription Hair Loss and Hair Removal Drugs, Share by Geographical Region 2015
  • Figure 8-6: The Worldwide Market for Prescription Hair Loss and Hair Removal Drugs Share by Geographical Region 2020
  • Table 8-7: Worldwide Market for Prescription Hair Loss and Hair Removal Drugs Revenues and Market Share by Supplier 2015
  • Figure 8-7: Worldwide Market for Prescription Hair Loss and Hair Removal Drugs Market Share by Leading Supplier 2015

CHAPTER NINE: PRESCRIPTION HYPERPIGMENTATION/MELASMA AND DEPIGMENTING DRUGS

  • Table 9-1: Common Prescription Hyperpigmentation/Melasma Formulations
  • Table 9-2: Common Prescription Depigmenting Agents
  • Table 9-3: The Worldwide Market for Prescription Hyperpigmentation/Melasma and Depigmenting Drugs by Type 2013-2020
  • Figure 9-1: The Worldwide Market for Prescription Hyperpigmentation/Melasma and Depigmenting Drugs Revenues by Type 2013-2020
  • Figure 9-2: The Worldwide Market for Prescription Hyperpigmentation/ Melasma and Depigmenting Drugs, Share by Type 2015
  • Figure 9-3: The Worldwide Market for Prescription Hyperpigmentation/Melasma and Depigmenting Drugs Share by Type 2020
  • Table 9-4: The Worldwide Market for Prescription Hyperpigmentation/Melasma Drugs by Geographical Region 2013-2020
  • Figure 9-4: The Worldwide Market for Prescription Hyperpigmentation/Melasma Drugs Revenues by Geographical Region 2013-2020
  • Figure 9-5: The Worldwide Market for Prescription Hyperpigmentation/Melasma and Depigmenting Drugs, Share by Geographical Region 2015
  • Figure 9-6: The Worldwide Market for Prescription Hyperpigmentation/Melasma and Depigmenting Drugs, Share by Geographical Region 2020

CHAPTER TEN: PRESCRIPTION PSORIASIS DRUGS

  • Table 10-1: Selected Common Prescription Psoriasis Preparations Selected Common Prescription Psoriasis Preparations
  • Table 10-2: Common Prescription Biologics for Psoriasis Treatment
  • Table 10-3: Prescription Psoriasis Preparations in Development
  • Table 10-3 (cont): Prescription Psoriasis Preparations in Development
  • Table 10-4: The Worldwide Market for Prescription Psoriasis Drugs by Type 2013-2020 273
  • Figure 10-1: The Worldwide Market for Prescription Psoriasis Drugs Revenues by Type 2013-2020
  • Figure 10-2: The Worldwide Market for Prescription Psoriasis Drugs Share by Type 2015 275
  • Figure 10-3: The Worldwide Market for Prescription Psoriasis Drugs Share by Type 2020 276
  • Table 10-5: Top Five EU Countries Prescription Psoriasis Markets by Revenues and Percent 2015
  • Table 10-6: Top Four Rest of World Countries Prescription Psoriasis Markets by Revenues and Percent 2015
  • Table 10-7: The Worldwide Market for Prescription Psoriasis Drugs by Geographical Region 2013-2020
  • Figure 10-4: The Worldwide Market for Prescription Psoriasis Drugs Revenues by Geographical Region 2013-2020
  • Figure 10-5: The Worldwide Market for Prescription Psoriasis Drugs Share by Geographical Region 2015
  • Figure 10-6: The Worldwide Market for Prescription Psoriasis Drugs Share by Geographical Region 2020
  • Table 10-8: Worldwide Market for Prescription Psoriasis Drugs Revenues and Market Share by Supplier 2015
  • Figure 10-7: Worldwide Market for Prescription Psoriasis Drugs Market Share by Leading Supplier 2015

CHAPTER ELEVEN: PRESCRIPTION SKIN CANCER DRUGS

  • Table 11-1: Malignant Conditions of the Skin
  • Table 11-2: Common Prescription Topical, Intralesional and Other Skin Cancer Agents . 296
  • Table 11-3: Prescription Skin Cancer Preparations in Development
  • Table 11-3 (continued): Prescription Skin Cancer Preparations in Development
  • Table 11-4: The Worldwide Market for Skin Cancer Drugs 2013-2020
  • Figure 11-1: The Worldwide Market for Skin Cancer Drugs 2013-2020
  • Table 11-5: Top Five EU Countries Prescription Psoriasis Markets by Revenues and Percent 2015
  • Table 11-6: Top Four Rest of World Countries Prescription Psoriasis Markets by Revenues and Percent 2015
  • Table 11-7: The Worldwide Market for Prescription Skin Cancer Drugs by Geographical Region 2013-2020
  • Figure 11-2: The Worldwide Market for Prescription Skin Cancer Drugs Revenues by Geographical Region 2013-2020
  • Figure 11-3: The Worldwide Market for Prescription Skin Cancer Drugs Share by Geographical Region 2015
  • Figure 11-4: The Worldwide Market for Prescription Skin Cancer Drugs Share by Geographical Region 2020
  • Table 11-8: Worldwide Market for Prescription Skin Cancer Drugs Revenues and Market Share by Supplier 2015
  • Figure 11-5: Worldwide Market for Skin Cancer Drugs Market Share by Leading Supplier 2015

CHAPTER TWELVE: MISCELLANEOUS SKIN DISORDER DRUGS

  • Table 12-1: Common Prescription Dermatological Systemic and Topical Antiviral Formulations
  • Table 12-2: Common Prescription Topical Antiparasitic Formulations
  • Table 12-3: Common Prescription Other Skin Formulations
  • Table 12-4: Prescription Miscellaneous Skin Preparations in Development
  • Table 12-5: The Worldwide Market for Prescription Miscellaneous Skin Disorder Drugs by Type 2013-2020
  • Figure 12-1: The Worldwide Market for Miscellaneous Skin Disorder Drugs Revenues by Type 2013-2020
  • Figure 12-2: The Worldwide Market for Miscellaneous Skin Disorder Drugs Share by Type 2015
  • Figure 12-3: The Worldwide Market for Miscellaneous Skin Disorder Drugs Share by Type 2020
  • Table 12-6: Top Five EU Countries Prescription Miscellaneous Skin Disorder Drug Markets by Revenues and Percent 2015
  • Table 12-7: Top Four Rest of World Countries Prescription Miscellaneous Skin Disorder Drug Markets by Revenues and Percent 2015
  • Table 12-8: The Worldwide Market for Prescription Miscellaneous Skin Disorder Drugs by Geographical Region 2013-2020
  • Figure 12-4: The Worldwide Market for Prescription Miscellaneous Drugs Revenues by Geographical Region 2013-2020
  • Figure 12-5: The Worldwide Market for Prescription Miscellaneous Drugs Share by Geographical Region 2015
  • Figure 12-6: The Worldwide Market for Prescription Miscellaneous Drugs Share by Geographical Region 2020

CHAPTER THIRTEEN: WORLD MARKET SUMMARY

  • Table 13-1: The Worldwide Market for Prescription Dermatological Drugs, Revenues by Segment, 2013-2020
  • Figure 13-1: The Worldwide Market for Prescription Dermatological Drugs Revenues by Dermatological Segment 2013-2020
  • Figure 13-2: The Worldwide Market for Dermatological Drugs Market Share by Type 2015
  • Figure 13-3: The Worldwide Market for Dermatological Drugs Market Share by Type 2020
  • Table 13-2: Worldwide Prescription Dermatological Drug Market Analysis by Region/Country, 2015
  • Figure 13-4: Worldwide Prescription Dermatological Drug Market Analysis by Region/Country, 2015
  • Figure 13-5: Worldwide Prescription Dermatological Drug Market Analysis by Region/Country, 2020
  • Table 13-3: Worldwide Market for Prescription Dermatological Drugs Segments of Major Participation by Manufacturer 2015
  • Table 13-4: Worldwide Market for Prescription Dermatological Drug Revenues and Market Share by Supplier 2015

LIST OF COMPANIES

Back to Top